Barry, OppHub America Desk · · Source: yahoo-tickers-tape-movers
Eli Lilly Named Top Compounder Stock by Jim Cramer
Investors may monitor Eli Lilly (:) given Jim Cramer's positive commentary and the company's market position in -1 treatments.
Based on reporting from yahoo-tickers-tape-movers.
Jim Cramer highlighted Eli Lilly and Company (NYSE:LLY) on September 8 as a premier compounder, attributing its strength to its GLP-1 weight-loss and diabetes treatments. He likened the pharmaceutical giant to a star running back, underscoring its robust growth and market position. This commentary comes as Lilly continues to expand its global reach for key medications.
Market context for this story
As of: WeekendLoading quotes…
Informational only — not investment advice. Full markets →
Lilly (Eli)·$LLY$LLYLilly (Eli)
TradingView
Live chart & market data via TradingView · OppHub classroom · Delayed or exchange real-time per TradingView data agreements · Not investment advice
Educational TradingView chart — search any symbol in the widget. Confirm on /markets/LLY. Not investment advice.
Related markets
Shares a vertical MP4 loop to your phone's camera roll or app share sheet (Instagram, TikTok, Facebook Reels).
Jim Cramer, in his September 8 "Mad Money" episode, identified Eli Lilly and Company (NYSE:LLY) as a significant "running back" stock within investor portfolios. Cramer's assessment centers on the company's success with its GLP-1 drugs, used for weight loss and diabetes management, positioning Lilly as a top-tier compounder.
### Story Arc / How We Got Here Eli Lilly's weight-loss drug Foundayo launched in the UK on August 10, marking its initial European availability for private prescriptions. This follows previous global expansion efforts for the company's therapeutic areas. This commentary from Jim Cramer on September 8 builds upon the ongoing narrative of Lilly's growth drivers.
### Money Play Investors may watch Eli Lilly (NYSE:LLY) as the company continues to navigate the GLP-1 market, with analyst commentary potentially influencing short-term sentiment.
### Catalyst Analysis: Analyst Commentary Jim Cramer's direct endorsement of Eli Lilly as a "top-tier compounder" provides a narrative boost for the stock. His comparison to a "running back" emphasizes the reliable and significant growth attributed to the company's GLP-1 franchise.
### Technical Analysis & Key Risk Watch
166.01 · R1 ## Technical Analysis & Key Risk Watch 150.63 · last ## Technical Analysis & Key Risk Watch 149.36 · S1 ## Technical Analysis & Key Risk Watch 147.00 · S2 ## Technical Analysis & Key Risk Watch 140.74.
Eli Lilly (NYSE:LLY) is trading near key support levels, with its last price at $1149.36. The stock has key support at $1147.00 (S1) and $1140.74 (S2), while resistance is seen at $1150.63 (R1) and $1166.01 (R2). The 14-day RSI is at 43.4, indicating a neutral momentum.
### Impact on Pharmaceuticals Eli Lilly's prominence in the GLP-1 market positions it as a bellwether for the broader pharmaceutical sector, particularly within the burgeoning obesity and diabetes treatment space.
### Story Arc / How We Got Here
This follows our earlier coverage ([Eli Lilly's Weight-Loss Drug Foundayo Launches in UK](/explore/eli-lillys-weight-loss-drug-foundayo-launches-in-uk)) on 2026-09-05. Eli Lilly and Company (NYSE:LLY) has launched its oral weight-management and type 2 diabetes treatment, Foundayo (orforglipron), in the United Kingdom, marking the drug's first availability in Europe. The launch follows authorization by the UK medicines regulator on August 10, making the treatment accessible via private prescription. · - Eli Lilly (:LLY) has seen its stock trade higher, supported by ongoing product launches and growth in its key therapeutic areas. Investors will monitor the global rollout of Foundayo and its impact on Lilly's market position in the lucrative weight-management…
Read the full story
Original reporting and related coverage — attribution links only, not paid recommendations.
Trade this story
Robinhood
Webull
Tradier
IBKR
Chart this story
TradingView
Broker and exchange buttons use invite / refer-a-friend links (rewards may be capped). Charting links (TradingView) are partner offers that may pay OppHub America a commission at no extra cost to you.
OppSHOP
Full OppSHOP →As an Amazon Associate, OppHub America earns from qualifying purchases. Shopping here helps keep the site free — at no extra cost to you. Disclosure
OppSHOP
Related to this story
Investors may monitor Eli Lilly (:) given Jim Cramer's positive commenta
Shop related →
Investing books
Read the classics
Shop this pick →
Personal finance books
Run the household books
Shop this pick →
Trading notebooks
Write the thesis first
Shop this pick →
Monitor for charts
See every pane
Shop this pick →
Story playbook
A pre-built map of what to watch — stocks, ETFs, and educational next steps. Not personalized advice.
Snapshot date: September 12, 2026 at 8:01 AM ET
This playbook was built when the story published and is not live-updated. Prices, news, and risk can change after this date — treat it as a starting map, not a current trade ticket.
Story → money map
weight loss drugs
A well-known financial commentator praised Eli Lilly for making popular weight-loss and diabetes drugs that make a lot of money. People who invest are paying attention because these successful products help the company grow fast.
What changed
Jim Cramer endorsed Eli Lilly as a top-tier compounder stock on Mad Money due to its strong GLP-1 franchise.
Who wins / who loses
Eli Lilly and healthcare sector peers benefit from high demand for weight-loss drugs, while traditional pharmaceutical companies lacking strong GLP-1 portfolios may lag.
Time horizon
Think in terms of the next few months.
Confidence & best fit
high confidence · Long-term investor, Active trader
Safer theme exposure (ETFs)
Baskets that own the theme without betting on one company.
Single stocks (higher risk)
Primary = closest to the story · Peers = same industry · Second-order = knock-on effects · Avoid = looks related but may be a trap
Primary
- $LLYWatch — track, don’t rush
The main company making these popular weight-loss drugs is getting a lot of positive attention.
View $LLY chart → · End-of-day delayed data
Peer
- $NVOWatch — track, don’t rush
The other giant company making the exact same kind of popular weight-loss medicine.
View $NVO chart → · End-of-day delayed data
Second-order
- $PFEStay away — for now
Older drug makers that might lose investor money to newer, faster-growing diet pill companies.
View $PFE chart → · End-of-day delayed data
Options (education only)
No strikes or expiries — a framework for how traders might express the view. Options can expire worthless.
Direction: bullish · Style: Debit spread (defined risk) · Level: intermediate
Buying options can be risky and expensive for beginners; if you are new, it is usually safer to just watch or buy regular shares instead.
Income / OppHub America angle
Not a trade tip — ways to use the insight outside the market.
- Research suppliers and contract manufacturers supporting the GLP-1 supply chain.
What would break this thesis
- Regulatory roadblocks or manufacturing supply shortages for GLP-1 drugs could quickly stall momentum.
What to do next on OppHub America
Saved playbooks stay on this device for now.
Important
Not financial advice. OppHub America playbooks are educational market maps only — not recommendations to buy, sell, or hold any security. Markets move fast; information can be wrong or outdated. Trade and invest at your own risk. Do your own research or consult a licensed advisor.
Based on reporting from yahoo-tickers-tape-movers.
Informational and educational only — not investment, financial, or legal advice. Disclosure
Shares a vertical MP4 loop to your phone's camera roll or app share sheet (Instagram, TikTok, Facebook Reels).